End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
2.02 USD | -3.35% | -4.04% | -8.18% |
05-12 | Transcript : Can-Fite BioPharma Ltd. - Special Call | |
05-09 | Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study | CI |
Sales 2024 * | 900K 1.23M | Sales 2025 * | 900K 1.23M | Capitalization | 10.91M 14.86M |
---|---|---|---|---|---|
Net income 2024 * | -7M -9.54M | Net income 2025 * | -8M -10.9M | EV / Sales 2024 * | 12.1 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 12.1 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.97% |
Latest transcript on Can-Fite BioPharma Ltd.
1 day | -3.35% |
Managers | Title | Age | Since |
---|---|---|---|
Motti Farbstein
CEO | Chief Executive Officer | 59 | 03-07-31 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
Abraham Sartani
BRD | Director/Board Member | 76 | 00-12-31 |
Ilan Cohn
FOU | Founder | 68 | 94-09-10 |
Pnina Fishman
FOU | Founder | 74 | 94-09-10 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.29% | 89.87B | |
-3.95% | 37.57B | |
-13.07% | 32.75B | |
+63.05% | 26.47B | |
-22.14% | 14.25B | |
-7.96% | 12.99B | |
-9.33% | 11.93B | |
-46.33% | 10.84B | |
+5.77% | 9.11B |
- Stock Market
- Equities
- CANF Stock
- CANF Stock